Whats your point big boy, that still isn't a do over. Insmed knew that there were plenty to recruit that had been prescribed the standard drug cocktail, but didn't anticipate so many had completely quit taking their prescription BECAUSE it didn't work.... and often made them sicker.... It's good that Insmed is recruiting patients that haven't just been prescribed a multi drug regimen - they are actually taking it
Yesterday Zake posted that Insmed had stubbed it's toe by having to do this trial over.... ..This is what can happen if someone reads enough posts from the babbling baboon. They see so many lies that they begin to accept the lies as truth. The current phase III trial wasn't botched and it isn't a do over, it is simply taking longer to enroll properly, and all of this was addressed more than 4 months ago.
The Novartis podhaler, original Tobi, Cayston..... each works well, but from day 1 when Insmed purchased Transave back in 2010 the basis for wanting to get arikayce approved for CF was that CF patients need alternatives because they are living longer and develop a resistance....
Really Zake, you want bwd to expand on why saying that CF is still on the table won't draw the ire of a particular poster here?
lol, for sure an oops moment BWD, but I would think that even a CEO would look at his trade confirmation at the time of the purchase plus he had to file the initial purchase. I think the oops moment was back in February, but who knows for sure?
These 10b-5 plans are set up when the filer has no material information, but allows the purchases to happen even if he is privvy to material information at the time the plan calls for purchases to be made. The initial trade happened over a month ago, and Lewis honored the trade (lucky broker) and didn't cancel the plan until over a month later. Either his budget doesn't allow for the additional purchases, in which case he should have cancelled the plan a month ago, or he may now hold material information and has been advised to cancel the plan since the original purchase covered the intended purchase price of the entire plan. That entire month between purchase number one and today's filing has me wondering....
Zake, I have never been anyone but bohemianclubman and when Terry goes from morning to night portraying himself as a trading expert I think responding that he often shows confusion between long and short positions is 100% warranted. Not a single one of those recs came from me, but clearly show the disdain from other posters regarding his non stop braggadocio attitude and non objective negativity regarding this stock. Usually I try to make clearly stated observations regarding INSM, but I admit that occasionally I stumble - sorry
I know that you don't like me and the feeling is very much mutual. That said, would you just do a small favor for another human being? I read your posts. I do. Sometimes I laugh. Sometimes I get mad. Sometimes I actually try to picture what a person with your obsession here.....looks like. Is it to embarrassing for you to ever leave your computer and go out.... in public? All of that said, it is so hard for me to justify reading stock posts from a poster that doesn't know the difference between long and short..... Would you please, please, please just take a few minutes away from this message board and google both so that you stop sounding so .....dumb..... Thanks Much!!!!!
Today's action really does point out the insignificance of one day's trading, suddenly INSM is up better than the market over the past two days....
Well, I guess that as much as I often want to argue with obsession man's posts, there is no use whatsoever arguing with a person that actually uses this term on a public message board - "The accumulation of shares long" Hey obsession man, go accumulate some shares short!!!
No H, I've never yet been to Blue Chip although I have heard all good things about it.... I guess that if I had a bucket list spending a few days there would be on it.
lol, H, you have to be one of the more tolerant people ever..... someone, of course, was bizarro boy, and yes Leerink had an outperform and still has an outperform.... It's old news anyway since the price target was cut a week ago and was part of quite a few price cuts due to overall sector weakness, not because they have suddenly changed their opinion of Insmed. I'm glad for your post though, since I was about to blast the obsessive one, calling him every name that yahoo allows to be posted, only to have it deleted within minutes.
I thought that was a great post....fud. With all the ravings from bizarro boy regarding "delays", and waiting for "phase III trials" , "limited labels", "no CF" and all the other bs he throws out there simply to feed his obsession, it sometimes may be a good idea to look closely at the simplicity and common sense of the company's longer term business model.
Taking already approved drugs and making them more effective through the Insmed technology makes virtually every single lung affliction a potential target for the Insmed liposome technology. I noticed MRSA listed on the 10K as a potential additional disease the company is closely looking at, and I know that MRSA caused pneumonia has been on a steep rise. Vancomycin, like amikacin, has many pitfalls when administered by injection or orally.
When the FDA ruled several years ago that arikayce was not an amikacin substitute but rather a whole new drug, it was notice of a long delay to get arikayce to market but it also made hundreds of other drugs fair game for the liposome technology.
I am anxious for Insmed to bring it's first new drug to market since iPLEX, but also confident that making existing drugs more effective continues to look to me like a longer term wealth builder.
and nothing has changed - the most obsessive message board poster in the history of history continues to spend his entire life on this message board, making it a lesser tool for those that just want to discuss what is happening with Insmed. Frustrating..... just like he wants it to be